Thumbnail Image
Publication

Semi-synthetic vNAR libraries screened against therapeutic antibodies primarily deliver anti-idiotypic binders.

Könning, Doreen
; 
Rhiel, Laura
; ; 
Grzeschik, Julius
; 
Sellmann, Carolin
; 
Schröter, Christian
; 
Zielonka, Stefan
; 
Dickgießer, Stephan
; 
Pirzer, Thomas
; 
Yanakieva, Desislava
... show 2 more
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2017-08-29
Submitted date
Show all metadata
Files
Thumbnail Image
Open Access publication
Adobe PDF, 2.94 MB
Other Titles
Abstract
Anti-idiotypic binders which specifically recognize the variable region of monoclonal antibodies have proven to be robust tools for pharmacokinetic studies of antibody therapeutics and for the development of cancer vaccines. In the present investigation, we focused on the identification of anti-idiotypic, shark-derived IgNAR antibody variable domains (vNARs) targeting the therapeutic antibodies matuzumab and cetuximab for the purpose of developing specific capturing ligands. Using yeast surface display and semi-synthetic, CDR3-randomized libraries, we identified several highly specific binders targeting both therapeutic antibodies in their corresponding variable region, without applying any counter selections during screening. Importantly, anti-idiotypic vNAR binders were not cross-reactive towards cetuximab or matuzumab, respectively, and comprised good target recognition in the presence of human and mouse serum. When coupled to magnetic beads, anti-idiotypic vNAR variants could be used as efficient capturing tools. Moreover, a two-step procedure involving vNAR-functionalized beads was employed for the enrichment of potentially bispecific cetuximab × matuzumab antibody constructs. In conclusion, semi-synthetic and CDR3-randomized vNAR libraries in combination with yeast display enable the fast and facile identification of anti-idiotypic vNAR domains targeting monoclonal antibodies primarily in an anti-idiotypic manner.
Citation
Semi-synthetic vNAR libraries screened against therapeutic antibodies primarily deliver anti-idiotypic binders. 2017, 7 (1):9676 Sci Rep
Affiliation
Helmholtz-Institut für pharmazeutische Forschung Saarland, Universitätscampus E8.1, 66123 Saarbrücken, Germany.
Publisher
Journal
Scientific reports
URI
http://hdl.handle.net/10033/621123
DOI
10.1038/s41598-017-10513-9
PubMed ID
28852148
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
2045-2322
EISSN
ISBN
ISMN
Gov't Doc #
Sponsors
License
Collections
publications of the research group drug design and optimization(HIPS]DDOP)